Lessons From a Career Dedicated to Transforming Heart Failure Care

In the latest episode of Moving the Needle in Medicine, host Alex Hajduczok, MD, a cardiologist and heart failure specialist at Oklahoma Heart Institute, sits down with Philip Adamson, MD, MSc, chief medical officer at CVRx, to discuss Adamson’s path through cardiology and his work with CVRx in heart failure.

Check out the full episode on Adamson’s full cardiology career here.

Hajduczok and Adamson discuss the transformative potential of baroreflex activation therapy in heart failure, highlighting a patient case from the Oklahoma Heart Institute that demonstrated substantial physiologic improvements following Barostim therapy. They describe marked gains in exercise capacity, with the patient nearly doubling maximal workload during invasive cardiopulmonary exercise testing, alongside a significant reduction in pulmonary capillary wedge pressure. The case is presented as a powerful illustration of the broad physiologic effects of neuromodulation, reinforcing the concept that heart failure is a complex, systemic disease requiring interventions capable of influencing multiple interconnected pathways. Rather than targeting a single aspect of cardiac function, baroreflex activation therapy is described as modifying pulmonary vascular responses, left atrial and ventricular physiology, heart rate regulation, and exercise tolerance simultaneously. The speakers emphasize that understanding these effects requires a strong foundation in cardiovascular pathophysiology and express enthusiasm about completing and publishing the case report to share these findings with the broader heart failure community.

The conversation then shifts from clinical science to professional development, as Adamson reflects on a career spanning academic medicine, clinical research, industry, and innovation. Although his work has evolved over several decades and across different settings, he explains that the central purpose of his career has remained unchanged: finding better ways to improve the lives of patients with heart failure. Adamson notes that each transition provided new opportunities to expand his perspective while remaining focused on advancing patient care. In particular, his experience in industry exposed him to areas beyond traditional clinical practice, including international regulatory processes, reimbursement strategies, medical device development, and the challenges of bringing new technologies from clinical investigation into widespread clinical adoption. He describes these experiences as invaluable, providing a broader understanding of the many factors required to successfully translate innovation into meaningful clinical impact.

The speakers also explore the value of curiosity, resilience, and lifelong learning in both medicine and research. Reflecting on his career, Adamson stresses that failures and missteps should not be viewed as permanent setbacks but rather as opportunities to refine one's thinking and improve future decision-making. He emphasizes the importance of remaining intellectually flexible, acknowledging that long-held hypotheses may ultimately prove incorrect and that unexpected opportunities often emerge for those willing to recognize them. Drawing on the analogy of noticing "red cars" only after intentionally looking for them, he encourages clinicians and investigators to remain attentive to new possibilities rather than becoming constrained by preconceived expectations.

Throughout the discussion, Adamson conveys a deep sense of gratitude for witnessing the remarkable evolution of heart failure care over the past four decades. He recalls entering the field at a time when heart failure was widely regarded as a rapidly progressive and uniformly fatal condition with limited therapeutic options. In contrast, contemporary advances have dramatically improved survival, functional status, and quality of life, with some patients now achieving meaningful recovery. He concludes that these advances have reinforced the purpose that has guided his career from the beginning: continually seeking new ways to help patients live longer, healthier, and more fulfilling lives despite the challenges of heart failure.

Editors’ Note: Hajduczok reports disclosures with CVRx, Edwards Lifesciences, and Impulse Dynamics. Adamson reports employment with CVRx.